Pharmacokinetics of (S)-9-[2-(phosophonylmethoxy) ethyl]adenine (PMEA) and zidovudine (AZT) when administered in combination

R. M. Lush, B. Y. Nguyen, K. C. Cundy, S. Bauza, T. Sogocio, J. Stevens, S. C. Piscitelli, D. J. Venzon, R. Yarchoan, W. D. Figg*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


The pharmacokinetics of (S)-9-[2-(phosophonylmethoxy)ethyl]adenine (PMEA) and zidovudine (AZT) were studied in patients receiving combination therapy with these agents. PMEA was administered as a thirty minute infusion three times weekly, and AZT (100 mg) was administered five times daily. The pharmacokinetics of AZT were studied prior to PMEA therapy, during the first week of combination therapy, and in the fourth week of combination therapy. PMEA concentrations were determined using HPLC and AZT concentrations by fluorescence polarization immunoassay. Data from four patients are available for this analysis. No difference was found in the pharmacokinetics of either AZT or PMEA when administered alone or in combination. Median estimates for AZT and PMEA terminal half-life are 0.63 and 1.57 hours, respectively. This study in four patients found no evidence of a drug interaction between AZT and PMEA.

Original languageEnglish
Pages (from-to)13-18
Number of pages6
JournalJournal of Applied Therapeutics
Issue number1
StatePublished - 1996
Externally publishedYes


  • 9-(2 phosophonylmethoxyethyl) adenine
  • AZT
  • HIV
  • PMEA
  • Pharmacokinetics
  • Zidovudine


Dive into the research topics of 'Pharmacokinetics of (S)-9-[2-(phosophonylmethoxy) ethyl]adenine (PMEA) and zidovudine (AZT) when administered in combination'. Together they form a unique fingerprint.

Cite this